Five Models That Prove Profit and Purpose Can Coexist

The development sector lacks proof that profit and purpose can coexist. It lacks the institutional courage to act on that proof.

Across three decades in international development, and most recently in converting medical device companies from passive donors into strategic revenue-generating members at the G4 Alliance, where the shift produced 24% revenue growth and 90% retention, I have watched the same pattern repeat: a sector that documents successful earned-revenue models, nods approvingly at the data, and then returns to the grant proposal queue. The models exist. They work. What is missing is the willingness to name profit as a legitimate instrument of mission, not a corruption of it.

Five organizations have already answered the question boards that are still open. Here is what they built, and what the rest of the sector is choosing not to learn from them.

1. Licensing mission-driven innovations

PATH’s vaccine vial monitor (VVM) is a textbook case of an NGO invention that became both a global public good and a sustainable commercial enterprise. Working with WHO and technology partners since the late 1970s, PATH developed temperature-sensitive stickers that indicate whether a vaccine vial has been compromised by heat. By 1996, these labels were commercially available for oral polio vaccines at a few cents per vial, eliminating enormous wastage and preventing unsafe doses from reaching children.

Licensing the donor-funded innovation to a specialist manufacturer created a revenue stream and secured global distribution capacity that no NGO could have built alone. PATH retained its role as an innovation steward. The private company earned profit by manufacturing and scaling technology. Profit here is not a tax on impact; it is the mechanism that keeps life-saving technology in production.

2. Pooled procurement that shapes markets

Gavi, the Vaccine Alliance, demonstrates how aggregated demand can simultaneously save lives and create the stable commercial markets that make saving lives sustainable. By pooling procurement across low-income countries, providing assured funding, and coordinating centralized purchasing, Gavi drives down prices while securing a reliable supply of high-quality vaccines.

A 15-year review found that coordinated market interventions helped immunize around 80 million children per year by 2018, a sixteenfold increase from 2005, while the cost per child fell to roughly one-quarter of 2005 levels. Manufacturers receive longer-term contracts and predictable volumes, making it rational to invest in production capacity. Countries receive affordable vaccines and real bargaining power. This is not a trade-off between mission and market. It is a mission through market design.

3. Certification that pays producers back

Fairtrade International’s model monetizes trust and standards while channeling real resources back to the producers who generate that trust. Businesses using the FAIRTRADE label pay license fees that fund producer support and training, standard-setting, market development, and advocacy. On top of those fees, the Fairtrade Premium – a mandatory additional payment on certified products – must be invested in community-chosen projects, such as clean water, education, and infrastructure.

The commercial logic is straightforward: companies pay for a label that demonstrably boosts sales. Field experiments show that Fair Trade labeling increased coffee sales by roughly 10% in U.S. grocery stores. Farmers gain higher, more stable incomes and increased investment in local development. A “cost of doing business” becomes communal asset creation. Ethics translates directly into commercial value and back into impact.

4. Social enterprises and fee-based education

Save the Children Global Ventures (SCGV) was created specifically to move beyond one-off grants into investable, fee-based models aligned with children’s rights. Its portfolio includes Ngutu College in Australia, which redesigns its curriculum around Indigenous knowledge for vulnerable students, and Zeraki, an edtech company that digitizes school management and fee-payment systems across Africa. These enterprises earn revenue through school fees, subscriptions, and service contracts, while improving access to quality education in low-income and rural communities.

SCGV’s 2024 impact report notes that Zeraki now serves over 6,600 schools across Kenya, Uganda, and other African countries, most of them public and rural, and has supported more than 172,000 teachers. Fees keep the platforms viable and scalable. The impact-investor structure ensures any financial upside is tied to expanded access, not to exclusion. This is what patient capital looks like when it is deployed with clarity of purpose.

5. Impact ventures for climate, agtech, and fintech

Mercy Corps Ventures (MCV) is proof that NGOs can be credible early-stage investors without abandoning their mission. In fact, by deepening it. Founded in 2015, MCV invests in venture-led solutions that help underserved communities join the global economy, with a focus on adaptive agriculture, inclusive climate fintech, and climate-resilience technologies. As of late 2025, its portfolio of 41 early-stage ventures had collectively raised over $333.9 million in follow-on capital; 51% of its portfolio companies are female-founded.

These startups help smallholder farmers build resilience, expand access to digital financial services, and prepare communities for climate shocks, while operating on profitable business models. Mercy Corps contributes local knowledge, networks, and credibility. Founders bring technology and operational expertise. Investors bring capital. Profit is not incidental; it is the signal that these solutions can survive and scale without permanent subsidy.

The real barrier: courage, not models

Licensing, pooled procurement, certification, social enterprise, and impact venture funds. Five working models. Decades of evidence. Results that would make any board proud. And yet most of the sector treats earned revenue as an exotic exception rather than a strategic imperative.

The question facing boards and executive teams is no longer “Can profit and mission coexist?” That question has been answered, repeatedly, publicly, at scale. The real question is: “Do we have the institutional courage to adopt models that let us participate in the value we help create?”

As I wrote in Devex, aid saves lives, profit makes livelihoods thrive. The sector’s reluctance to say so out loud is a strategic failure with real consequences for the communities it claims to serve. This post is part of the Beyond Grants series, which explores new business models for global development. On April 14, I am convening a small group of C-suite practitioners at InterAction HQ in Washington, D.C., to take this conversation off the page, during World Bank/IMF Spring Meetings week. If this framing resonates with your work, I would welcome the conversation. #BeyondGrants #DevelopmentFinance #NonprofitLeadership #SustainableFinancing #SocialImpact #GlobalHealth